Literature DB >> 24768252

Comparative study of cognitive impairment between medicated and medication-free patients with remitted major depression: class-specific influence by tricyclic antidepressants and newer antidepressants.

Akiko Nagane1, Hajime Baba2, Yoshiyuki Nakano3, Hitoshi Maeshima3, Mana Hukatsu4, Kazuhiro Ozawa5, Toshihito Suzuki3, Heii Arai3.   

Abstract

Patients with major depressive disorder (MDD) are known to present with cognitive deficits; however, the presence of these deficits in the remitted state have been inconsistent. One of the most important factors potentially contributing to inconsistencies between studies may be the influence of medications. To explore the influence of antidepressants on cognitive performance in remitted MDD, we evaluated memory and executive functions using Wechsler Memory Scale-Revised and Stroop Color and Word Test, and compared performance among 50 medicated (29 treated with tricyclic antidepressants [TCA], 21 treated with selective serotonin reuptake inhibitors or serotonin noradrenalin reuptake inhibitors) and 19 medication-free MDD patients and 31 controls. The results showed that all 3 MDD groups had significantly lower performance for verbal memory compared with controls. Both medicated groups showed significantly lower performance for visual memory compared with controls; however, the medication-free group did not differ from controls. For the executive function, only the TCA group showed a significantly lower performance compared with controls. These results suggest that cognitive impairment remained even in remitted patients with MDD, however, part of this impairment may be influenced by class-specific antidepressant side effects.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antidepressant; Cognition; Depression; Executive function; Medication; Memory; Remission

Mesh:

Substances:

Year:  2014        PMID: 24768252     DOI: 10.1016/j.psychres.2014.04.013

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Older Adults' Perspectives on Clinical Research: A Focus Group and Survey Study.

Authors:  Eric J Lenze; Alex Ramsey; Patrick J Brown; Charles F Reynolds; Benoit H Mulsant; Helen Lavretsky; Steven P Roose
Journal:  Am J Geriatr Psychiatry       Date:  2016-07-29       Impact factor: 4.105

2.  Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs.

Authors:  Donatella Marazziti; Federico Mucci; Beniamino Tripodi; Manuel Glauco Carbone; Alessia Muscarella; Valentina Falaschi; Stefano Baroni
Journal:  Clin Neuropsychiatry       Date:  2019-04

3.  Depression and episodic memory across the adult lifespan: A meta-analytic review.

Authors:  Taylor A James; Samuel Weiss-Cowie; Zachary Hopton; Paul Verhaeghen; Vonetta M Dotson; Audrey Duarte
Journal:  Psychol Bull       Date:  2021-11       Impact factor: 23.027

4.  Anterograde Amnesia during Electroconvulsive Therapy: A Prospective Pilot-Study in Patients with Major Depressive Disorder.

Authors:  Elvira Boere; Astrid M Kamperman; Arianne E van 't Hoog; Walter W van den Broek; Tom K Birkenhäger
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

5.  Different patterns of attentional bias in antenatal and postpartum depression.

Authors:  Åsa Edvinsson; Alkistis Skalkidou; Charlotte Hellgren; Malin Gingnell; Lisa Ekselius; Mimmie Willebrand; Inger Sundström Poromaa
Journal:  Brain Behav       Date:  2017-10-18       Impact factor: 2.708

6.  A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets.

Authors:  Xiaohang Li; Qinying Wang; Tingting Hu; Ying Wang; Jian Zhao; Jing Lu; Gang Pei
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

7.  Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.

Authors:  Trisha Chakrabarty; Shane J McInerney; Ivan J Torres; Benicio N Frey; Roumen V Milev; Daniel J Müller; Susan Rotzinger; Sidney H Kennedy; Raymond W Lam
Journal:  CNS Drugs       Date:  2021-03-08       Impact factor: 5.749

Review 8.  Cognitive remission: a novel objective for the treatment of major depression?

Authors:  Beatrice Bortolato; Kamilla W Miskowiak; Cristiano A Köhler; Michael Maes; Brisa S Fernandes; Michael Berk; André F Carvalho
Journal:  BMC Med       Date:  2016-01-22       Impact factor: 8.775

9.  Cognitive functioning and lifetime major depressive disorder in UK Biobank.

Authors:  Laura de Nooij; Mathew A Harris; Mark J Adams; Toni-Kim Clarke; Xueyi Shen; Simon R Cox; Andrew M McIntosh; Heather C Whalley
Journal:  Eur Psychiatry       Date:  2020-02-21       Impact factor: 5.361

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.